

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases Manuscript NO: 85258 Title: Primary Adrenal Ewing Sarcoma: A Systematic Review of the Literature Provenance and peer review: Invited Manuscript; Externally peer reviewed Peer-review model: Single blind **Reviewer's code:** 00066723 **Position:** Editorial Board Academic degree: PhD Professional title: Associate Professor Reviewer's Country/Territory: Netherlands Author's Country/Territory: Greece Manuscript submission date: 2023-04-20 **Reviewer chosen by:** AI Technique Reviewer accepted review: 2023-04-27 11:40 Reviewer performed review: 2023-05-04 10:39 Review time: 6 Days and 22 Hours

| | [] Grade A: Excellent [Y] Grade B: Very good [] Grade C: |
|-----------------------------|--|
| Scientific quality | Good |
| | [] Grade D: Fair [] Grade E: Do not publish |
| Novelty of this manuscript | [Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No novelty |
| Creativity or innovation of | [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair |
| this manuscript | [] Grade D: No creativity or innovation |



| Scientific significance of the conclusion in this manuscript | [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance |
|--|---|
| Language quality | [Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection |
| Re-review | []Yes [Y]No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |

SPECIFIC COMMENTS TO AUTHORS

This systematic review reads well and summarizes information on clinicopathological data of a very rare disease Ewing sarcoma localized to the adrenal gland. The study emphasizes how little we know of these rare tumors and which severely hampers effective treatment. Comments: 1. Page 2, introduction, line 10 - Please mention some EWSR1-FLI1 target genes by name especially the ones involved in tumorigenesis.

2. Figure 1 – Clearly list eligibility criteria in the materials and methods section for the assessment of full text articles. 3. Page 5, results, line 2 - Here it says fifty-six studies were included whereas Figure 1 indicates n=55. Please check and correct. 4. Are primary adrenal Ewing sarcoma molecularly distinct from bone localized Ewing sarcomas? 5. Please briefly give some future prospects. What burning questions should be answered regarding this particular tumor? How should the field progress to improve management and treatment of these rare tumors?



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 85258

Title: Primary Adrenal Ewing Sarcoma: A Systematic Review of the Literature

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02979917

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2023-04-20

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-31 01:43

Reviewer performed review: 2023-06-06 09:59

Review time: 6 Days and 8 Hours

| | [] Grade A: Excellent [] Grade B: Very good [] Grade C: |
|-----------------------------|--|
| Scientific quality | Good |
| | [Y] Grade D: Fair [] Grade E: Do not publish |
| Novelty of this manuscript | [] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [Y] Grade D: No novelty |
| Creativity or innovation of | [] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair |
| this manuscript | [] Grade D: No creativity or innovation |



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

| Scientific significance of the conclusion in this manuscript | [] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No scientific significance |
|--|---|
| Language quality | [] Grade A: Priority publishing [] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection |
| Re-review | [Y]Yes []No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |

SPECIFIC COMMENTS TO AUTHORS

The authors reviewed the literature on primary adrenal ES/PNET over the past 30 years. And they further updated the diagnosis, treatment, and oncological outcomes of primary adrenal ES/PNET. While the clinical topic in the focus of this manuscript is certainly interesting, there are some issues to complete. And major revisions are needed.

1. It should be clearly identified in the title and manuscript that it is a systematic review of case reports and case series. 2. The detailed search strategy for each database should be listed in the supplementary table. 3. The PRISMA guidelines for reporting in systematic reviews are suggested to be used during the selection and data analysis phases. The format of the flow chart (Figure 1) should comply with the PRISMA flow chart. 4. The authors should cite the included references in the results. 5. The regional distribution of reported cases could be shown in a graph to be more intuitive.

6. The authors should record the overall number of patients in Table 1 and Table 2. The percentage of patients partly seems to be incorrect. And the style of Table 1 and Table 2 should also be adjusted. 7. The introduction mentioned the recent advances in molecular biology. However, the discussion did not mention how molecular biology can



guide novel therapeutic protocols. And also, how conventional therapeutic protocols, including radiotherapy, can be improved by novel techniques. Authors can refer to the articles below: Artificial intelligence in radiotherapy. Seminars in cancer biology, 86(Pt 2), 160–171. https://doi.org/10.1016/j.semcancer.2022.08.005 SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(14), e2004846. https://doi.org/10.1002/advs.202004846 Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature communications, 12(1), 3230. https://doi.org/10.1038/s41467-021-23445-w 8.There are some English mistakes. The English should be polished by native speakers or language experts.